How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?

Finn Gustafsson, Julian Segura, Luis M Ruilope

    14 Citationer (Scopus)

    Abstract

    An increasing number of patients in the community are being treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers for hypertension, coronary disease or diabetic renal and vascular complications. Some of these patients will develop heart failure despite such treatment. Based on data from hypertension trials it can be estimated that approximately 5% of treated patients will develop heart failure over 5 years. It is unclear whether patients developing heart failure on and off ACE-inhibitors or beta-blockers, respectively, at the time of heart failure diagnosis have similar prognosis.Treatment options for patients developing heart failure while already treated with ACE inhibitors/ARBs and beta-blockers are very limited if current heart failure guidelines are followed. In this review possible strategies are outlined and important areas for research are identified. It is suggested that trials are designed specifically to address prognosis and treatment in this growing population.
    OriginalsprogEngelsk
    TidsskriftJournal of Hypertension
    Vol/bind28
    Udgave nummer8
    Sider (fra-til)1595-8
    Antal sider4
    DOI
    StatusUdgivet - 1 aug. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?'. Sammen danner de et unikt fingeraftryk.

    Citationsformater